In this episode of ATTD 2025 Conference Catch-Up, we dive into Debate: Adaptive Trials in the Post-Teplizumab Era: To Placebo or Not to Placebo?, featuring a lively discussion on the ethics and necessity of placebo-controlled trials in type 1 diabetes research, with a focus on adaptive trial designs and the future of treatment testing.Join us as we summarize key takeaways from these thought-provoking presentations:Yes, We Should Continue with Placebo – Prof. Colin DayanNo, We Should Use Only Active (Approved) Control – Dr. Laura JacobsenRebuttal by Speaker Presenting the Case for 'Yes' – Prof. Colin DayanRebuttal by Speaker Presenting the Case for 'No' – Dr. Laura JacobsenThis episode is an essential listen for researchers, clinicians, and diabetes specialists interested in the future of clinical trial design, the ethical considerations in testing new treatments, and the evolving landscape of type 1 diabetes research.Enjoy the listen!This podcast was created using AI to provide a quick and insightful summary of an ATTD 2025 session. While every effort has been made to ensure accuracy, listeners are encouraged to refer to original conference materials and recordings for detailed information.ATTD 2025, the 18th International Conference on Advanced Technologies & Treatments for Diabetes, is taking place on March 19-22, 2025, in Amsterdam. https://attd.kenes.com

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related